Nirogacestat oral tablet

Phase 2

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Nirogacestat oral tablet is one of 2 therapeutic programs targeting Desmoid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Desmoid TumorActive, not recruiting

Desmoid TumorPhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Desmoid Tumor

#DrugCompanyPhaseTrials

Vivia

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Approved

5 2

Nirogacestat oral tablet

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Active, not recruiting

Desmoid Tumor

NCT07170644

Clinical

Trials by Indication[1]

Desmoid Tumor1 trial

A Single-arm, Open-label Phase 2 Study of Nirogacestat in Adult Japanese Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Active, not recruiting·SSpringWorks Therapeutics, Inc.·Phase 2·NCT07170644·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nirogacestat oral tablet. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Nirogacestat oral tablet. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Nirogacestat oral tablet

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Desmoid Tumor1 trial

References

Drug Info

Quick Facts

Related News